AbbVie’s Neuroscience Revenues Exceed 17% on Double-Digit Botox, Vraylar Growth
AbbVie’s neuroscience portfolio now contributes over 17% of total revenues, driven by double-digit sales growth in Botox, Vraylar, and its migraine therapy. This diversification bolsters AbbVie’s top-line expansion beyond its core immunology business in 2025.
1. Neuroscience Franchise Fuels Double-Digit Revenue Growth
AbbVie’s neuroscience portfolio now contributes more than 17% of consolidated revenues, driven by robust demand for Botox, Vraylar and its migraine therapy franchise. Botox U.S. unit sales increased by 12% year-over-year in the fourth quarter of 2025, while Vraylar prescriptions rose 25% globally. Migraine drug launch volumes expanded 30% sequentially as market share in chronic and episodic categories climbed to 18% based on IQVIA data. Management attributes this outperformance to targeted promotional investments and expanded patient support programs, forecasting neuroscience revenues in 2026 to exceed $15 billion, up from $12.8 billion in 2025.
2. Institutional Investors Adjust Positions in AbbVie
Generali Asset Management SPA SGR reduced its stake by 7.3% during the third quarter, selling 6,172 shares to hold 78,122 shares valued at approximately $18.09 million at quarter-end. In contrast, Banque Pictet & Cie SA increased its position by 89.2%, acquiring an additional 157,480 shares to total 333,971 shares worth $77.33 million. Together, these moves reflect ongoing portfolio rebalancing among major asset managers, with institutional ownership remaining at roughly 70% of outstanding shares.
3. Q3 Earnings Beat and Guidance Raise Support Upside
In its third-quarter report, AbbVie posted revenue of $15.78 billion, a 9.1% increase from the prior year period, driven by Humira, Skyrizi and Rinvoq growth. Adjusted earnings per share of $1.86 surpassed consensus by $0.09. The company raised its full-year EPS guidance range to $12.28–$12.38, up from $12.10–$12.30, reflecting stronger immunology and oncology performance. Management expects full-year revenue growth of 8%–9% and forecasts free cash flow exceeding $22 billion, underpinning capital returns and debt reduction plans.
4. Dividend Increase Underscores Commitment to Shareholders
AbbVie declared a quarterly dividend of $1.73 per share, up 5.5% from the prior payout, with an annualized yield of approximately 3.0%. The payment will be made to shareholders of record on January 16, 2026, supporting a dividend payout ratio near 50% of adjusted net income. This marks the 55th consecutive year of dividend growth when including predecessor company payouts, reinforcing AbbVie’s status as a high-income equity for long-term investors.